Latest News

Nuvilex Begins Preclinical Studies at Translational Drug Development

Nuvilex Begins Preclinical Studies at Translational Drug Development

SILVER SPRING, Md., Aug. 20, 2014 — Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex’s unique cancer treatment can slow the accumulation of fluid, known as “malignant ascites,” in the abdomen that is characteristic of the growth of many abdominal tumors.

Kenneth L. Waggoner, CEO and President ...

Read More →
0

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Written by ι Stock Market Media Group Staff — July 7, 2014

Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company’s “global development partners” at the 2014 BIO International Convention in San Diego.  One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex’s plans for treating diabetes.  This, of course, begs the question − is Nuvilex in line for ...

Read More →
0

ForeverGreen Worldwide Continues to Outperform While New Report Shows It Remains Undervalued

ForeverGreen Worldwide Continues to Outperform While New Report Shows It Remains Undervalued

Written by ι Stock Market Media Group Staff — June 2, 2014

ForeverGreen Worldwide Corp. (OTCQB: FVRG) recently raised its forecast for 2014 revenues to $41-50 million after yet another explosive quarter of growth.  While strong growth has become commonplace for the company, so too is ForeverGreen being undervalued.  Stock Market Media Group (SMMG), a full service research and content development IR firm, has announced that it is extending its coverage on ForeverGreen which began in May 2013, at $0.17/share.

In a new Report, ...

Read More →
0

National Automation Services Acquires Position in the Growing US Energy Revolution

National Automation Services Acquires Position in the Growing US Energy Revolution

Written by ι Stock Market Media Group Staff — June 2, 2014

National Automation Services, Inc. (OTCQB: NASV) (“NAS, Inc.”) officially became part of a burgeoning domestic energy revolution when it acquired JD Field Services earlier this year.  This acquisition puts the company squarely in the middle of an industry that’s enjoying myriad growth and attention in the U.S.; it’s a boom that shows no signs of slowing any time soon.  NAS, Inc. has intimated that it plans to continue acquiring companies in ...

Read More →
0

Social Networking Giant Twitter and Online Deals Upstart LiveDeal Join Competitive Index Wars

Social Networking Giant Twitter and Online Deals Upstart LiveDeal Join Competitive Index Wars

Written by ι Stock Market Media Group Staff — June 2, 2014

Last Friday it became official for two tech companies that joined the index wars as additions to the Morgan Stanley Capital International (MSCI) global index.  MSCI, one of the world’s largest equity index providers, had its annual May “shake up” where it rebalanced its many global indices with each index receiving a list of additions and deletions.  Two such additions were the well-known social networking platform Twitter (NYSE: TWTR) and the ...

Read More →
0

Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients

Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients

Written by ι Stock Market Media Group Staff — May 23, 2014

Nuvilex (OTCQB: NVLX) is calling it a “two pronged attack” on pancreatic cancer, but investors may be calling it an “end-around” or another avenue of sorts, a quicker avenue to FDA approval.  This week Nuvilex peeled back another layer of its work with pancreatic cancer, and this time it was to tell the market that the well-respected Translational Drug Development (TD2) will be studying the company’s pancreatic cancer treatment, the combination ...

Read More →
0
Page 1 of 48 12345...»